Objective: Parkinson's disease (PD) has long been conceptualized as a motor disorder, but nonmotor symptoms also manifest in the disease and significantly reduce quality of life. Anxiety and cognitive dysfunction are prevalent nonmotor symptoms, even in early disease stages, but the relation between these symptoms remains poorly understood. We examined self-reported anxiety and neurocognitive function, indexed by measures of executive function (set-shifting and phonemic fluency), categorical fluency, and attention/working memory. We hypothesized that anxiety would correlate with cognitive performance. Method: The Beck Anxiety Inventory and cognitive tests (Trail Making, Verbal Fluency, Digit Span) were administered to 77 nondemented adults with mild to moderate idiopathic PD (39 men, 38 women; M age ϭ 62.9 years). Results: Higher anxiety was associated with more advanced disease stage and severity and with poorer set-shifting when using a derived metric to account for motoric slowing. Depression correlated with greater anxiety and disease severity, but not with cognitive performance. Conclusions: Our findings support the association of anxiety with a specific domain of executive function, set-shifting, in nondemented individuals with mild to moderate PD, raising the possibility that treatment of anxiety may alleviate aspects of executive dysfunction in this population.
Afflicting approximately 1% of the population over age 60 (Mayeux, 2003; Prediger, Matheus, Schwarzbold, Lima, & Vital, 2012 ), Parkinson's disease (PD) is associated with classic motor symptoms as well as with a variety of nonmotor symptoms, including cognitive dysfunction and neuropsychiatric symptoms (Cronin-Golomb, 2013) . Nonmotor symptoms are often comorbid with one another, with increased comorbidity associated with greater disease severity as indexed by motor and functional measures (Shulman, Taback, Bean, & Weiner, 2001 ). These nonmotor symptoms significantly contribute to a poor quality of life in individuals with PD (Duncan et al., 2014) , often to a greater extent than the motor symptoms (Bonnet & Czernecki, 2013; Qin et al., 2009 ), but they remain understudied and underdiagnosed (Shulman, Taback, Rabinstein, & Weiner, 2002) . In particular among the nonmotor symptoms, anxiety and cognitive dysfunction are highly prevalent in PD, even in the early stages of the disease. Emerging research is beginning to more closely consider cognitive impairment and affective disorders in this population (Bogdanova & Cronin-Golomb, 2012 , 2013 Pluck & Brown, 2002; Santangelo et al., 2009 ), but the literature remains limited (Poletti, De Rosa, & Bonuccelli, 2012) .
Although the relation between anxiety and cognitive function is not well characterized in PD, anxiety has long been associated with impaired cognitive performance in non-PD populations, particularly on attentionally demanding tasks (Derakshan & Eysenck, 2009) . In older adults, including those with mild cognitive impair-ment (MCI), anxiety has been associated with cognitive deficits (Forsell, Palmer, & Fratiglioni, 2003) and has also been shown to predict cognitive decline in individuals without depression or cognitive impairment (Sinoff & Werner, 2003) . There is some evidence that those who develop anxiety disorders later in life (age 55 and above; an age group that includes most individuals with PD) may exhibit poorer overall cognition than those with early onset anxiety disorders (DeLuca et al., 2005) , suggesting that anxious individuals with PD may be at an increased risk for cognitive dysfunction due to their age alone. Specifically, individuals with anxiety disorders exhibited impairments in executive function and episodic memory (Airaksinen, Larsson, & Forsell, 2005) , and older adults with generalized anxiety disorder showed impairments in short-term and working memory, information processing speed, inhibition and problem-solving, and immediate and delayed memory, compared to control adults (Butters et al., 2011; Caudle et al., 2007; Mantella et al., 2007) . These findings suggest that anxiety and cognition are likely to also be related in PD.
The lack of research on affective symptoms in PD is concerning, as clinically significant anxiety occurs in up to 40% of individuals with PD (Aarsland, Marsh, & Schrag, 2009; Walsh & Bennett, 2001) , and anxiety disorders occur at higher rates in PD than in the overall population (Nuti et al., 2004; Walsh & Bennett, 2001) . Anxiety in PD contributes to reduced subjective quality of life (Carod-Artal, Ziomkowski, Mourao Mesquita, & Martinez-Martin, 2008; Dissanayaka et al., 2010; Hanna & Cronin-Golomb, 2012; Havlikova et al., 2011; Leentjens, Dujardin, Marsh, MartinezMartin, et al., 2011; McKinlay et al., 2008; Pontone et al., 2009) and greater self-perceived disability (Witjas et al., 2002) . Of further concern in PD, anxiety may compromise information processing ability and thereby negatively affect gait, potentially leading to falls (Ehgoetz Martens, Ellard, & Almeida, 2015) . Anxiety can also co-occur with depression in PD (Dissanayaka et al., 2010; Menza, Robertson-Hoffman, & Bonapace, 1993) , and clinically significant depressive symptoms occur at rates of 35% in this population (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008) . Consideration of comorbid depression is important, given that depression in PD has been associated with cognitive decline (Starkstein, Mayberg, Leiguarda, Preziosi, & Robinson, 1992) , and with executive dysfunction and working memory deficits, even in early disease stages (Dirnberger & Jahanshahi, 2013; Uekermann et al., 2003) .
Cognitive dysfunction occurs in the majority of individuals with PD (Mamikonyan et al., 2009 ). Up to 57% of those with PD are affected by MCI within the first 3-5 years after diagnosis (Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007) , and up to 14% of individuals with PD over age 65 develop some type of cognitive impairment each year (Galvin, 2006) . Cognitive deficits in PD are associated with greater motor severity and typically include executive dysfunction, visuospatial and constructional deficits, and attention/working memory deficits (Dirnberger & Jahanshahi, 2013; Muslimovic, Post, Speelman, & Schmand, 2005; Pfeiffer, Løkkegaard, Zoetmulder, Friberg, & Werdelin, 2014) . Visuospatial, attentional, and executive deficits are the most typical in PD individuals with MCI (Aarsland, Brønnick, & Fladby, 2011) . In a study of individuals with mild to moderate PD with neither dementia nor MCI, measures of attention and executive function (frontal-type tests) were the most sensitive to cognitive compromise (Miller, Neargarder, Risi, & Cronin-Golomb, 2013 ).
Understanding cognitive deficits in the early stages of the disease is important because they may predict the progression of cognitive dysfunction to dementia (Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 2003; Kehagia, Barker, & Robbins, 2010; Levy et al., 2002; Williams-Gray et al., 2007 ).
Regarding potential mechanisms, similar brain regions and neurotransmitter systems have been implicated in the development of anxiety and cognitive dysfunction in PD and in the overall population, suggesting that the symptoms may be related in PD, at least in part, as a result of shared underlying neurocircuitry. First, disrupted frontostriatal circuitry likely contributes to the executive deficits in nondemented individuals with PD, including deficits in flexibility, planning, and working memory (Kehagia, Barker, et al., 2010) . Specifically, these impairments have been associated with prefrontal dopaminergic dysregulation (Cools, Barker, Sahakian, & Robbins, 2001; Narayanan, Rodnitzky, & Uc, 2013) and basal ganglia dysfunction (Kehagia, Barker, et al., 2010; Obeso, Rodriguez-Oroz, Rodriguez, Arbizu, & Gimenez-Amaya, 2002; Obeso et al., 2000) . At the same time, widespread Lewy-body pathology occurs in PD in brain areas associated with anxiety, such as the amygdala, which has major projections to the prefrontal cortex (Braak et al., 1994; Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004; Pontone et al., 2009; Prediger et al., 2012) , suggesting potential disruption to affective and cognitive functioning. Emerging work also points to a potential role of dopaminergic degeneration in the ventral tegmental area in the pathophysiology of nonmotor symptoms in PD, namely depression, anxiety, and executive dysfunction (Alberico, Cassell, & Narayanan, 2015) .
The sources of mild cognitive deficits in early stage PD may also include structural changes in frontal and temporoparietal regions as well as nondopaminergic dysfunction (Hanna-Pladdy, Jones, Cabanban, Pahwa, & Lyons, 2013) . Noradrenaline and serotonin have been implicated in the development of anxiety in PD and the general population (Millan, 2003; Prediger et al., 2012; Ressler & Nemeroff, 2000) . Specifically, noradrenergic dysfunction has been implicated in deficits in attentional set-shifting, such as the task-switching deficits observed in individuals with PD (Kehagia, Cools, Barker, & Robbins, 2009; Kehagia, Murray, & Robbins, 2010) . In PD, noradrenergic dysfunction has been associated with depression and anxiety (Remy, Doder, Lees, Turjanski, & Brooks, 2005) , and also with cognitive impairment and dementia (Del Tredici & Braak, 2013) . Likewise, serotonergic dysfunction occurs early in PD and may contribute to anxiety, considering the projections from the serotonergic raphe nuclei to corticolimbic regions (Prediger et al., 2012) . Serotonergic neuronal loss has the potential to compromise cognition as well (Halliday, Leverenz, Schneider, & Adler, 2014) , based on reduced levels of serotonin observed in PD in key brain regions, such as the hippocampus and frontal cortex (Scatton, Javoy-Agid, Rouquier, Dubois, & Agid, 1983) .
To date, the limited research on affective symptoms and cognitive function in PD has investigated the effects of depression and apathy on cognition, with relatively minimal attention given to the study of anxiety and cognition in this population (Poletti et al., 2012) . In the present study, we sought to expand our understanding of this relation in a relatively large sample of individuals with PD. We focused on executive functioning (set-shifting, phonemic fluency) and attention/working memory, as deficits in these domains are usually the cognitive symptoms that are documented in mild to This document is copyrighted by the American Psychological Association or one of its allied publishers.
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moderate PD (Miller et al., 2013) . The main hypothesis was that higher anxiety levels would correlate with poorer performance on neuropsychological measures of executive function and attention.
Method Participants
Participants included 77 nondemented individuals with PD (39 men, 38 women; M age ϭ 62.9 years, SD ϭ 7.4), who were referred from the Parkinson's Disease Center of Boston Medical Center and local PD support groups. These individuals were participants in studies that used partly overlapping measures of cognition, as well as the same measure of anxiety. The study protocols were approved by the Boston University Institutional Review Board, with consent obtained according to the Declaration of Helsinki.
Participants with PD met the clinical criteria for mild to moderate idiopathic disease, following the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria (Hughes, Daniel, Kilford, & Lees, 1992) . Exclusion criteria included coexisting serious chronic illness (including psychiatric or neurological); use of psychoactive medications besides antidepressants and anxiolytics, which are commonly prescribed in PD; history of intracranial surgery, traumatic brain injury, alcoholism or other drug abuse; and visual acuity poorer than 20/40. All participants were nondemented, as indicated by scores of 25 or better on a standard cognitive screening measure, the Mini-Mental State Examination (Folstein, Folstein, & McHugh, 1975) and performance on the several cognitive tests described below.
Motor disability was staged using the Hoehn and Yahr (H&Y) Scale (Hoehn & Yahr, 1967) . There were 15 participants in Stage I (unilateral), 51 in Stage II (mild bilateral), and 11 in Stage III (moderate bilateral). Of the 77 participants, 40 had motor symptom onset on the left body side (LPD), 36 on the right side (RPD), and one had bilateral onset. All were tested in their "on" medication state. Disease and motor disability was rated with the Unified Parkinson's Disease Rating Scale (UPDRS; Fahn & Elton, 1987) . UPDRS scores were available for 45 out of 77 participants. UP-DRS total score (Sections 1-3) was used as a measure of overall disease severity, and the motor subscale (Section 3) was used as a measure of motor symptom severity. Levodopa equivalent dosages (LEDs) were calculated using a standard formula (Tomlinson et al., 2010) ; medication information was available for 39 out of 77 participants. Of these 39 participants, five were taking anti-anxiety medication, and three were taking antidepressant medication. Table 1 provides a summary of participant characteristics.
Procedure and Measures
Following the administration of the Mini-Mental State Examination, participants completed a series of neuropsychological tests and mood questionnaires. The neuropsychological tests assessed current cognitive functioning primarily in the domains of executive functioning, working memory, and attention because these were the tests for which we had been collecting data across studies for several years, which permitted us to examine a large sample. Not all participants received all tests.
Tests of attention and working memory included the Trail Making Test (TMT)-A and Digit Span Forward and Backward.
Tests of executive functioning included the TMT-B and Phonemic Fluency. Category Fluency was also administered.
We administered the Digit Span subtest from the Wechsler Memory Scale III (Wechsler, 1997) to assess attention (forward and backward conditions) and working memory (backward condition). Score for each condition was the total number of correct trials. The TMT (Tombaugh, 2004) was given to evaluate attention, set-shifting, and executive function. The task was to quickly draw lines connecting numbers in order (TMT-A; attention), and then to alternate between numbers and letters in order (TMT-B; set-shifting, executive function). Score for each was time to completion. To isolate set-shifting measured by TMT-B, a derived TMT-difference score was calculated (TMT-B Ϫ TMT-A), which removes the psychomotor component of the task that is captured in TMT-A (O'Rourke et al., 2011). To further assess executive function, participants engaged in the Word Association Test for phonemic fluency (Delis, Kaplan, & Kramer, 2001 ). They were instructed to name as many unique words beginning with the letters F, A, and S (FAS; phonemic fluency) as possible. The categorical fluency trial was also administered, which required participants to name as many unique animals (categorical fluency; Animals) as possible. The time limit for each trial was 60 s. Score for phonemic fluency was the total number of correct responses, summed across the F, A, and S trials. Score for categorical fluency was the total number of correct responses.
To measure anxiety symptoms, participants were administered the Beck Anxiety Inventory (BAI; Beck & Steer, 1993) . The BAI is a 21-item self-report measure of anxiety, on which higher scores indicate more anxiety symptoms. Participants also were given the Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, This document is copyrighted by the American Psychological Association or one of its allied publishers.
1996) to assess current depressive symptoms. The BDI-II is a 21-item self-report measure of depressive symptoms, with higher scores indicative of higher levels of depression.
Data Analysis
Statistical analyses were conducted with SPSS Version 23. Correlational analyses were conducted to determine whether neurocognitive functions were related to symptoms of anxiety. The relation between anxiety and cognitive performance was examined using correlational analyses. The skew in the BAI score distribution dictated the use of nonparametric analyses (Spearman's correlations). The sample size for each analysis was dependent upon the number of individuals who had been administered those particular cognitive tests. For the 77 PD participants, the sample size for each analysis ranged from 57 to 62. By test, the sample sizes were as follows: TMT-A: 62; TMT-B: 62; FAS: 59; Animals: 57; Digit Span Forward: 58; Digit Span Backward: 58. To account for the number of analyses and correlations between outcome variables, we used a conservative alpha level of .01 because some of the tests belonged to the same cognitive domain. Because some participants did complete all of the cognitive tests, a conservative alpha level was used to minimize Type I error rate.
Results

Within-Group Levels of Anxiety and Depression
The mean BAI in the sample was 10.0 (SD ϭ 7.7). Twelve of the 77 PD participants reported clinically significant levels of anxiety on the BAI when using a highly specific cutoff score of 18 (Higginson, Fields, & Tröster, 2001 ). Four of the 12 had clinically significant depression scores (BDI-II Ն17). In this subgroup of 12, mean BDI-II was 15.2 (SD ϭ 7.9), mean age was 65.8 years (SD ϭ 9.8), mean education was 14.4 years (SD ϭ 2.4), mean disease duration was 10.9 years (SD ϭ 8.4), and all were in H&Y Stages II or III. Of these 12 with clinically significant anxiety, nine completed TMT-A and TMT-B, and seven completed Verbal Fluency (FAS and Animals) and Digit Span.
The mean BDI-II in the sample was 8.2 (SD ϭ 6.2). Clinically significant levels of depression were reported by eight of the participants on the BDI-II, using a highly specific cutoff score of 17 (Higginson et al., 2001 ). Four of the eight had clinically significant anxiety scores (BAI Ն18).
Within the PD group, levels of anxiety did not differ for men versus women, t(75) ϭ .09, p ϭ .93 or by side of motor symptom onset (LPD, RPD): t(74) ϭ 1.07, p ϭ .29. Depression levels did not differ between men and women with PD, t(75) ϭ 1.71, p ϭ .09, or by side of motor symptom onset (LPD, RPD): t(74) ϭ .03, p ϭ .98. Age at testing did not correlate with anxiety ( ϭ -.14, p ϭ .23). Data were accordingly collapsed across gender, side of motor symptom onset, and age for the following analyses.
Within-Group Correlational Analyses
Anxiety correlated with certain clinical characteristics, as shown in Table 2 . These included disease stage (H&Y), disease severity (UPDRS total), and depression, with higher anxiety associated with more advanced stage, more severe disease, and higher depression. Anxiety also correlated with education and disease duration at a trend level, with higher anxiety associated with lower education and longer disease duration. Anxiety was not associated with medication usage (LED) or motor symptom severity. Depression correlated with disease severity ( ϭ .47, p ϭ .001) and there was a trend for a correlation with motor symptom severity ( ϭ .32, p ϭ .03), but not with age, education, disease duration, medication usage, or disease stage (all ps Ͼ .05; see Table 3 ).
Because demographic and mood variables may influence neuropsychological performance, we conducted correlational analyses to examine these potential effects in our PD sample. Age, education, medication usage (LED), motor symptom severity, and overall disease severity (UPDRS total) did not correlate with cognitive performance (all s Յ |.26|, ps Ն .04); UPDRS and LED correlational analyses were conducted with the subset of participants for whom those data were available. Disease stage (H&Y) correlated with performance on TMT-B ( ϭ .37, p ϭ .003), and there were trends for TMT-B Ϫ TMT-A ( ϭ .29, p ϭ .02) and category fluency ( ϭ -.31, p ϭ .02), but not for other cognitive tests (all s Յ |.22|, ps Ն .087). There were trends for disease duration to correlate with TMT-B ( ϭ .29, p ϭ .02) and TMT-B Ϫ TMT-A Figure 1 ), and remained significant after removing the psychomotor component of the task (TMT-B Ϫ TMT-A: ϭ .34, p ϭ .007; Table 4 ). Anxiety did not correlate with performance on the tests of phonemic fluency, categorical fluency, attention, or working memory (see Table 4 ). Depression did not correlate with performance on any of the cognitive measures (see Table 5 ). The pattern of findings remained the same after excluding the eight participants with clinically significant depression scores, such that there was a trend for anxiety to correlate with TMT-B ( ϭ .32, p ϭ .016) and TMT-B Ϫ TMT-A ( ϭ .33, p ϭ .016), but not with other cognitive measures (all s Յ |.23|, ps Ն .11).
Discussion
We examined the relation between anxiety and cognitive functioning in a large, well-characterized sample of nondemented individuals with mild to moderate idiopathic PD. Higher anxiety was significantly associated with more advanced disease stage and severity, and there was a trend for anxiety to also be associated with lower education and longer disease duration. Anxiety also correlated with depression, and depression was associated with greater disease severity, with a trend for an association with motor symptoms as indexed by the UPDRS motor subscale. Regarding cognitive function, higher anxiety correlated with poorer setshifting (TMT-B) among PD participants even after removing the psychomotor component of the cognitive task (TMT-B Ϫ TMT-A). Anxiety level did not correlate with performance on tests of attention, working memory, phonemic fluency, or categorical fluency. Depression did not correlate with cognitive performance, which is likely related to floor effects as the mean depression score in our sample was well within normal limits.
We had originally predicted an association between anxiety and executive and attentional dysfunction in PD. Our results are consistent with a recent study by Martens and colleagues (2016) that reported a correlation between anxiety and TMT-B Ϫ TMT-A in PD, but no significant correlations between anxiety and the digit span subtests. Our findings with a relatively large number of measures of executive function and attention (including digit span) accord with and expand upon those of the study of Martens and colleagues, highlighting the specific association between anxiety and set-shifting in mild to moderate PD. The relation between anxiety and TMT-B is consistent with attentional control theory (Eysenck, Derakshan, Santos, & Calvo, 2007) , which asserts that anxiety decreases attentional control and increases attention to threat, thereby compromising cognitive processes including inhibition and shifting. Consistent with this theory, in a sample of community-dwelling older adults, individuals with increased anxiety showed poorer processing speed/shifting attention and inhibition abilities (Beaudreau & O'Hara, 2009) , which is in keeping with the association we observed between anxiety and set-shifting in our PD sample.
An earlier paper from our lab examined anxiety and cognition as related to side of motor symptom onset in PD (Bogdanova & Cronin-Golomb, 2012) . A consistent finding was the relation between disease duration and anxiety, which was observed in the 2012 sample and at a trend level in the present sample, suggesting that the relation between anxiety and cognition may evolve as the disease progresses. The current study, relative to the 2012 study, included a larger sample of individuals with mostly mild anxiety in early disease stages, with analyses collapsed across side of motor symptom onset. We also included discussion of depression and motor symptoms when possible and used a derived metric to better isolate set-shifting and account for motor slowing. Of note, the present sample was similar to the 2012 sample in age and gender This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
distribution, but current participants were milder overall, as indexed by shorter disease duration (6.5 years compared to 8.7) and less advanced disease stage (H&Y Stages I-III compared to Stages II-III), which underscores the importance of studying anxiety and cognition even in the early stages of PD.
It is important to note that neuropsychological tests vary in their sensitivity to cognitive impairment in PD (Miller et al., 2013) ; hence, it is possible that some of our cognitive measures were not sensitive enough to capture the relation between anxiety and mild cognitive deficits in our sample of high-functioning, nondemented PD participants with mostly quite mild anxiety symptoms. In a sample of 42 nondemented PD participants and 28 control participants, 36% of the PD group showed deficits (defined at SD ϭ 1.5 below the control-group mean) on TMT-B, while only 15% showed deficits on Digit Span Forward and Digit Span Backward, suggesting that TMT-B performance may be affected to a greater extent than Digit Span in early PD (Miller et al., 2013) . Anxiety may impair cognitive performance, especially on complex or attentionally demanding tasks (Derakshan & Eysenck, 2009) , which may explain the observed association between anxiety and TMT-B, and the lack of association between anxiety and a relatively simple task (Digit Span Forward) in our sample. Although Digit Span Backward is also a demanding task, there was greater variability in our sample on TMT-B (SD ϭ 45.8) than Digit Span Backward (SD ϭ 2.8), which may have reduced the power to discern an association between anxiety and working memory. Likewise, although phonemic fluency is often impaired in early PD (Miller et al., 2013) , in our present sample there was considerably less variability in performance of this test (SD ϭ 11.5) than for TMT-B. It should be noted that the cognitive tests differ in their metrics and range of scores. Also, the reduced power of nonparametric analyses, the use of which was dictated by the data characteristics, may have limited our ability to detect significant correlations between anxiety and measures of fluency or attention.
Our study was subject to limitations. First, our cognitive assessment was restricted to tests of executive function, attention, and categorical fluency. We drew upon neuropsychological data from several years of consecutive participants, and these were the tests that were common across that time period. The advantage of the selection of the tests was the large sample size for whom anxiety and cognition in a particular domain could be examined. Future research on anxiety and cognition in PD should include a more comprehensive assessment of cognitive function, and in particular, measures of complex visuospatial function and reasoning, as deficits in these domains are regularly observed in PD (Amick, Miller, Neargarder, & Cronin-Golomb, 2012; Amick, Schendan, Ganis, & Cronin-Golomb, 2006; Bogdanova & Cronin-Golomb, 2012) . Second, our sample was assessed with only one measure of anxiety, the BAI, which includes several somatically based items, for example, "wobbliness in legs," "unsteady," "hands trembling," "shaky," which are similar to PD motor symptoms (e.g., tremor or feelings of unsteadiness; Leentjens et al., 2008; Salazar, Le, Neargarder, & Cronin-Golomb, 2017) . Mitigating this concern, we have found no difference in the ability of the BAI and its less somatically laden counterpart, the State-Trait Anxiety Inventory, to predict quality of life in mild to moderate PD (Hanna & Cronin-Golomb, 2012) . Future studies may consider inclusion of recently developed PDspecific anxiety scales, such as the Parkinson Anxiety Scale (Leentjens et al., 2014) . Third, our sample consisted of nondemented and mainly high-functioning individuals with PD who reported mostly mild to moderate levels of anxiety. The relation may be different in individuals with more advanced PD or more severe anxiety. Inclusion of a PD control group (e.g., nonanxious vs. highly anxious PD participants) may elucidate the effects of anxiety on cognition when controlling for the cognitive dysfunction associated with the disease itself (e.g., executive deficits due to frontostriatal disruption). Finally, information about disease severity (UPDRS) was available for the majority, though not all, of our participants with PD (45 out of 77), which limits our interpretation of the relation between anxiety, cognition, and motor symptom severity. Among the subset with UPDRS scores, motor symptom severity did not correlate with anxiety or cognition, nor was there a relation between anxiety and cognition, likely due to floor effects, as the BAI mean was quite low (6.6). We included the participants without UPDRS data to increase the range of BAI scores and examine the relation between anxiety and cognition in a larger PD sample.
Taken together, our results suggest that anxiety may be related to poorer performance on measures of set-shifting even in highfunctioning individuals with mild to moderate PD. With a better understanding of the manifestation of nonmotor symptoms in PD subgroups, we can hope to increase recognition of anxiety and cognitive dysfunction, particularly in the early stages of the disease, to inform subsequent treatment options. This is important because, as we have documented, anxiety may deleteriously affect quality of life to a greater extent than do the motor symptoms of PD (Hanna & Cronin-Golomb, 2012) . With research dedicated to a more comprehensive and systematic evaluation of anxiety and cognition in PD at various stages of the disease, we can work toward developing treatment approaches to address the often devastating effects of mood and cognitive impairments in PD, and ultimately improve daily functioning and quality of life for people living with this disorder.
